My health, my right. FC2 . . THE FEMALE HEALTH COMPANY Access to HIV prevention services is #myrighttohealth ———— HOUSE_OVERSIGHT_027074

OVERVIEW C2 ©... FEMALE HEALTH COMPANY HOUSE_OVERSIGHT_027075

WWW.FEMALECONDOM.COM GET INSPIRED Empowering Kenya https://fc2femalecondom.com/get-inspired/ https://youtu.be/OOV-KYyTza8 HOUSE_OVERSIGHT_027076

ASK Due to the funding decrease UNFPA is experiencing as the US pulled all their funding under president Trump, and the European countries have re-directed their funding to deal with the migrant influx, there is a funding shortfall leading to Female Condom stock outs in countries. The Female Health Company is looking for donors who are willing to donate money to UNFPA, and earmark that money for purchase of the FC2 female condom only, so that they can purchase the FC2 female condom for the following countries: Uganda : 3 million units Ghana: 1 million units Botswana: 1 million units Tunesia: 1 million units Sierra Leone: 500,000 units Bolivia: 500,000 units Tanzania: 1 million units Haiti: 500,000 units Ethiopia: 1 million units Congo DR: 2 million units HOUSE_OVERSIGHT_027077

The Female Health Company provides the FC2 female condom. FC2 is the only product currently available: Under a women’s control Offering triple protection: « Against HIV/AIDS = STIs (as well as ZIKA) = Unplanned pregnancy Approved by the FDA and WHO, as well as other international and national health agencies HOUSE_OVERSIGHT_027078

WIDEST POSSIBLE CHOICE FC2 falls under Reproductive Health Supply commodities with UNFPA Supplies: * Contraceptives - Combined low dose OC Pills - Emergency Contraceptives - Female Condoms - Lubricants - Progestogen only Pills * Diagnostic Test Kits * Kits * Medical Devices * Pharmaceutical Devices - Implantable Contraceptives - Injectable Contraceptives - Intrauterine Device (IUD) - Male Condoms HOUSE_OVERSIGHT_027079

MALE AND FEMALE CONDOM MARKETS Male Condom Market Global Public sector: 10 billion Male Condom Market FP2020, 69 countries: 1-1,6 billion Female Condom Market: 30-60 million FC is 3%-6% of FP2020 condom market and 0,3%-0,6% of global condom market Consumer Global Public Sector HIV/AIDS Global Market Family Planning Global Condom Public Health $4 — 6 Billion $ 400 — 500 Million Units ~10 — 12 Billion Units ~10 Billion HOUSE_OVERSIGHT_027080

CUSTOMERS AND DISTRIBUTION Key purchasers: = Global agencies = Government/ Ministries of Health = State and local health departments/agencies = NGOs and CBOs/IPPF/MSI = Distributors who hold registration for FC2 = Social marketing organizations such as PSI and DKT = Commercial partners that promote to consumers USAID 9” FROM THE AMERICAN PEOPLE HOUSE_OVERSIGHT_027081

WHY FEMALE CONDOMS? 1) The female condom is the only female initiated method that provides triple protection against STls including HIV and Zika and against unplanned pregnancy 2) Introduction of male and female condoms in the same market leads to more overall protected sex acts 3) Cost effective, positive return on investment THE FEMALE HEALTH COMPANY HOUSE_OVERSIGHT_027082

HIV/AIDS GLOBAL OVERVIEW ¢ No. 1 cause of death globally for women age 15-44 « 80% of female cases contracted via heterosexual transmission e Male and female condoms are the only prevention products available 48% 52% Worldwide, women represent >50% of new Male | Female Adult HIV/AIDS infections ONEVOICE HOUSE_OVERSIGHT_027083

THE SOCIAL CASE FOR FC2 Empowering women as a development tool by decreasing maternal mortality & fewer unwanted pregnancies and protecting from HIV-infection, and other STIs = Worldwide 215 million women who like to plan or limit number of children have no access to contraception = Worldwide 21.6 million unsafe abortions cause 5 million women hospitalized each year, and account for 13 % of maternal deaths = Worldwide women and girls account for slightly more than half of all HIV infections = In sub-Saharan Africa 23 million people live with HIV/AIDS: over 12 million are women and nearly 2.5 million are children HOUSE_OVERSIGHT_027084

THE PRODUCT CASE FOR FC2 1) Only FDA and WHO approved Female Condom and as a result approved for bulk procurement by UNFPA and USAID 2) The strong preference for FC2 due to its non allergenic material nitrile and long standing reputation 3) FC2 is has been distributed to 144 countries. 4) The backup support, materials, training provided by FHC HOUSE_OVERSIGHT_027085

THE PRODUCT CASE FOR FC2 (2) 5) The FC2 female condom, as opposed to the latex male condom, is made out of Nitrile which holds many benefits: 6) The FC2 is hormone free, which means that it does not have the side effects of some hormone based contraceptives. 7) Preferable alternative to a male condom, according to males = Men don’t have to wear it = Not tight/restricting = Can be inserted in advance of sexual activity Three times stronger than latex, Can be used by people who are latex sensitive, or allergic Can hold both water and oil based lubricants (latex tears with oil) Can be inserted hours in advance Transfers body heat ensuring a more natural sensation HOUSE_OVERSIGHT_027086

DEBUNKING MYTHS & MISCONCEPTIONS Certain Myths and Misconceptions among decision still exist today, even though the evidence tells otherwise It is too expensive There is no demand We already have male condoms and LARCs so the FC is not necessary Men do not like the product, and without them it will never succeed HOUSE_OVERSIGHT_027087

1) IT IS TOO EXPENSIVE: FALSE “The Business Case for Female Condoms” (Global Health Visions, 2014) Return on investment of female condom procurement for governments through 2 ways: 1) Cost savings to the health system, by focussing on prevention instead of treatment 2) Economic productivity losses averted, as more women are able to join the workforce. HOUSE_OVERSIGHT_027088

THE BUSINESS CASE FOR FEMALE CONDOMS (2) The Business case for female condoms found that for every $1,- invested in buying female condoms in Kenya a return of $1,94 is made. In Nigeria for every $1,- invested a return of $3,20 is made. See table below for health benefits. ondoms # DALYs averted 9,292 9,713 4,122 9,488 # of unintended 1,939 1,939 1,939 1,939 pregnancies averted #of HIV infections 108 125 62 100 averted #of maternal 4 2 7 deaths averted #of infant deaths 53 39 14 77 averted #of unsafe 243 265 521 213 abortions averted HOUSE_OVERSIGHT_027089

2) THERE IS NO DEMAND: FALSE Uruguay Study, UNFPA Uruguay and MOH Uruguay (2017): - 77% of average women said the FC2 was good or very good Study participants cited greater comfort and practicality and greater protection and safety as the two main advantages of the FC2 THE LATEST DATA ON FEMALE CONDOM ACCEPTABILITY , ‘Confirms: Female condoms have high acceptance rates, are in high demand by both women and ‘men, and provide women with triple protection: with the FC2, they have the autonomy to protect themselves from unplanned pregnancy as well as STs, including HIV & Zika. - 81% said they would continue using the FC2 in the future - 64 % said they experienced no difficulties at all South Africa National Female Condom Program Evaluation (2017) - 80% of women feld the FC put them in charge - The level of unprotected sex declined from 43,3 % at baseline to 8,4 % at 12 months after the introduction of the FC HOUSE_OVERSIGHT_027090

3) WE ALREADY HAVE OTHER COMMODITIES: FALSE AIGHD Research on the Female Condom in Mozambique (2017) The increase in female condom use was not accompanied by an off-setting decrease in ever or current use of alternative methods. If anything, current use of male condoms and other modern contraceptives increased slightly in the treatment group. Female condoms thus seemed to complement the existing choice set of regular contraceptives South Africa National Female Condom Program Evaluation (2017) Of the current FC users 73,4% reported using condoms in general more often than before they started using the female condom. HOUSE_OVERSIGHT_027091

4) MEN DO NOT LIKE THE PRODUCT: FALSE South Africa National Female Condom Program Evaluation (2017) At their one month interview 58% of men said that the FC was better or much better than the MC and at 12 months this rose to 74% At six months into the research 97% of women reported that their partners were supportive of using the FC HOUSE_OVERSIGHT_027092

IN SUMMARY 1) Female Condoms provide a return on investment 2) Female Condoms are in high demand with both men and women, average and key populations 3) Female Condoms increase the overall use of barrier methods and contraceptives, enforcing decrease in overall number of unprotected sex acts HOUSE_OVERSIGHT_027093